Pulse Biosciences, Inc. (PLSE)
NASDAQ: PLSE · Real-Time Price · USD
15.13
-0.03 (-0.20%)
Jul 23, 2025, 3:44 PM - Market open

Company Description

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.

It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians.

The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.

Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Pulse Biosciences, Inc.
Pulse Biosciences logo
CountryUnited States
Founded2014
IPO DateMay 18, 2016
IndustryMedical Instruments & Supplies
SectorHealthcare
Employees75
CEOPaul LaViolette

Contact Details

Address:
601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
United States
Phone510 906 4600
Websitepulsebiosciences.com

Stock Details

Ticker SymbolPLSE
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001625101
CUSIP Number74587B101
ISIN NumberUS74587B1017
Employer ID46-5696597
SIC Code3841

Key Executives

NamePosition
Paul Arthur LaViolettePresident, Chief Executive Officer, Principal Executive Officer, Principal Financial Officer and Co-Chairman of the Board
Robert W. DugganIndependent Co-Chairman
Darrin R. UeckerChief Technology Officer and Director
Kevin P. DanahyChief Commercial Officer and Principal Executive Officer
Jon SkinnerChief Financial Officer
Edison ManuelVice President of Operations
Dr. Richard Nuccitelli Ph.D.Chief Science Officer
Kenneth B. Stratton Esq., J.D.General Counsel and Corporate Secretary
Patty PerlaVice President of Human Resources
Mitchell E. LevinsonChief Strategy Officer

Latest SEC Filings

DateTypeTitle
Jul 14, 20258-KCurrent Report
Jun 13, 2025144Filing
Jun 12, 2025144Filing
May 30, 2025SDForm - SD
May 8, 202510-QQuarterly Report
May 8, 20258-KCurrent Report
Apr 30, 202510-K/A[Amend] Annual report
Mar 31, 202510-KAnnual Report
Mar 28, 20258-KCurrent Report
Feb 27, 2025S-8Securities to be offered to employees in employee benefit plans